TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33971993
Drug: Extra-virgin olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-virgin olive oil group (30 ml/d of extra-virgin olive oil + healthy diet)
Study: 33206059
Drug: Recommended care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended care with telerehabilitation (including a weekly group teleconference session)
Study: 33261578
Drug: Animal-Assisted Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-Assisted Therapy (AAT) with a bird for eight weeks
Study: 32624377
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine patch (10 μg/h)
Study: 32624377
Drug: Oral celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral celecoxib
Study: 36103665
Drug: Restylane Lyft
Normalized name: Restylane
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restylane Lyft (1 ml on day 1, re-treatment of 0.5 ml at month 12)
Study: 36103665
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control (1 ml offered at month 6)
Study: 33798509
Drug: Dextrose gel
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose gel (200 mg/kg)
Study: 35144326
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual + Rhemercise (n=63)
Study: 35144326
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual only (n=63)
Study: 34874419
Drug: High-flow oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow oxygen therapy through a nasal cannula
Study: 33642340
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Vitamin C
Study: 33351209
Drug: VITILSI© gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: VITILSI© gel 2 x day
Study: 33351209
Drug: VITILSI© gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: VITILSI© gel 2 x day + Bioskin© 1 x week
Study: 35302901
Drug: Intraoperative injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative injection of autologous microfragmented adipose tissue
Study: 35302901
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no injection of autologous microfragmented adipose tissue)
Study: 33221969
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + nintedanib
Study: 32698123
Drug: α-lactalbumin (LA)
Normalized name: alpha-lactalbumin (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lactalbumin (LA) 40 g
Study: 32698123
Drug: Collagen peptide
Normalized name: Procollagen peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen peptide (CP) 40 g
Study: 35182721
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg i.v. on day 1 with neoadjuvant carboplatin and nab-paclitaxel
Study: 32861716
Drug: C2238 ANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2238 ANP allele (homozygous CC)
Study: 34585595
Drug: loteprednol‐etabonate 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: loteprednol‐etabonate 0.5% twice daily for 14 days tapered to once daily for 14 days, and then twice weekly for 28 days
Study: 32722454
Drug: 8% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% carbohydrate (CHO) solution (5 mL/kg/bw)
Study: 32722454
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) solution (flavour and appearance-matched, 5 mL/kg/bw)
Study: 89012353
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B immune globulin and vaccine on schedule
Study: 89012353
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B immune globulin and vaccine off schedule
Study: 34699967
Drug: Albuterol/budesonide (180/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol/budesonide (180/160 µg)
Study: 34699967
Drug: Albuterol/budesonide
Normalized name: ALBUTEROL/BUDESONIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol/budesonide
Study: 34397827
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia (IH)
Study: 34570180
Drug: Methylphenidate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (10 mg, twice daily)
Study: 32175680
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of edaravone with taurine
Study: 33562090
Drug: Fermented powdered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented powdered soy product (12.5 g each, 2 packets daily)
Study: 36228310
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day (Group 1)
Study: 36228310
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day (Group 2)
Study: 36228310
Drug: 5 mg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/week (Group 3)
Study: 36099688
Drug: Acceptance-enhanced behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-enhanced behavior therapy for TTM (AEBT‐TTM)
Study: 38761558
Drug: Psychoeducation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation and supportive therapy (PST)
Study: 34050429
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia (TEA) with continuous epidural bupivacaine and sufentanil infusion
Study: 34050429
Drug: Paravertebral analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral analgesia (PVA) with continuous paravertebral bupivacaine infusion and intravenous morphine
Study: 35590794
Drug: Ringer’s solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer’s solution
Study: 35590794
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no liquid administered)
Study: 34656955
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg MOFs daily for 3 months
Study: 34656955
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg MOFs
Study: 34332956
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg bolus then 0.12 mg/kg/h infusion for the first 24 hours postoperative
Study: 34332956
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg and Mg sulfate 50 mg/kg, then ketamine 0.12 mg/kg/h and Mg sulfate 8 mg/kg/h infusions for the first 24 hours postoperative
Study: 34428440
Drug: Text message-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message-based support (4 texts per week for 6 months) covering diet, physical activity, smoking, general cardiovascular health, and medication adherence.
Study: 34264865
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg oral methylphenidate
Study: 34653245
Drug: OVX836 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: OVX836 (30 µg, 90 µg, or 180 µg)
Study: 32331244
Drug: Standard antenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antenatal GDM management (insulin/metformin)
Study: 34403046
Drug: Treatment effects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effects on pH
Study: 33270066
Drug: Thommen Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thommen Implant System
Study: 36257846
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no supplemental treatment)
Study: 32039724
Drug: Metformin (1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1700 and 2000 mg/d)
Study: 32039724
Drug: Metformin exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin exposure
Study: 36351721
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of human-derived neural stem cells (hNSCs) for 4 consecutive weeks
Study: 35737872
Drug: 5% sodium
Normalized name: Dextrose 5% and 0.45% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sodium fluoride (NaF) varnish with standard oral hygiene instructions (OHI)
Study: 35737872
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral hygiene instructions (OHI)
Study: 34261354
Drug: Inoculation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoculation with 20 μl of 10^6 conidia/ml suspensions of C. fioriniae and C. nymphaeae isolates
Study: 33444189
Drug: Gluten-free diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten-free diet (GFD) including at least 6 gluten-free breads per day + 200g of gluten-free penne pasta per week + 6 rice flavour capsules per day
Study: 33444189
Drug: Gluten-containing diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten-containing diet including at least 6 gluten-containing breads per day + 200g of gluten-containing penne pasta per week + 6 vital gluten-containing capsules per day
Study: 36170749
Drug: mART (maternal
Approvals — FDA: no, EMA: no, PMDA: no
Description: mART (maternal antiretroviral therapy)
Study: 36408821
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of HR20033
Study: 35681162
Drug: Stratified exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified exercise therapy (including dietary intervention for the 'obesity subgroup')
Study: 35681162
Drug: Stratified exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified exercise therapy (for the 'obesity subgroup')
Study: 35681162
Drug: Stratified exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified exercise therapy (for the 'high muscle strength subgroup')
Study: 35681162
Drug: General knee
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: General knee OA treatment
Study: 33098189
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with less than 20% decline in 3-IGI PRO score after two treatment cycles
Study: 32513226
Drug: Intensive face-to-face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive face-to-face sessions (mean dose delivered 10.9 of 12 sessions)
Study: 32513226
Drug: Maintenance phone
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance phone calls (mean dose delivered 7.7 of 9 calls)
Study: 32513226
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intensive sessions (>6) and maintenance calls (>8)
Study: 32513226
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (zero dose)
Study: 38606412
Drug: Learning Through
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Learning Through Play plus Culturally adapted Cognitive Behaviour Therapy (LTP+CaCBT)
Study: 33358255
Drug: Long-term cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term cilostazol treatment
Study: 33358255
Drug: High high-sensitivity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High high-sensitivity chronic reactive protein level, diabetic neuropathy, sole use of an oral hypoglycemic agent, and lack of supervised exercise
Study: 33721199
Drug: 80 IU
Normalized name: Ascorbic Acid/Garlic/Vitamin A/Vitamin E 160 MG-300 MG-5280 IU-40 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 IU intranasal insulin
Study: 34071485
Drug: Enriched yogurt
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enriched yogurt with PAF inhibitors from olive pomace
Study: 35774049
Drug: Standard optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard optimal medical therapy (OMT)
Study: 32959589
Drug: Preoperative acupoint
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative acupoint application therapy
Study: 32959589
Drug: Postoperative acupoint
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative acupoint application therapy
Study: 37753446
Drug: OAC discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC discontinuation
Study: 33355910
Drug: Tegoprazan 200
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 200 mg
Study: 34436536
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg orally once daily) plus Letrozole (2.5 mg orally once daily)
Study: 34436536
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg orally once daily)
Study: 36271335
Drug: Oral esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral esomeprazole 20 mg, twice-daily for 36 weeks (Group D)
Study: 36271335
Drug: Oral esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral esomeprazole 20 mg, once-daily for 36 weeks (Group S)
Study: 35314817
Drug: Fortacin™ (prilocaine/lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortacin™ (prilocaine/lidocaine spray) - 3 sprays administered 5 min before intercourse
Study: 35314817
Drug: Fortacin™ (prilocaine/lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortacin™ (prilocaine/lidocaine spray) - 3 sprays administered 15 min before intercourse
Study: 35314817
Drug: Fortacin™ (prilocaine/lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortacin™ (prilocaine/lidocaine spray) - 3 sprays administered 30 min before intercourse
Study: 35314817
Drug: Fortacin™ (prilocaine/lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortacin™ (prilocaine/lidocaine spray) - 1 spray administered 5 min before intercourse
Study: 35314817
Drug: Fortacin™ (prilocaine/lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortacin™ (prilocaine/lidocaine spray) - 5 sprays administered 5 min before intercourse
Study: 33811367
Drug: Saroglitazar 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saroglitazar 1 mg
Study: 33160341
Drug: HIV prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV prevention methods (including condoms and daily oral PrEP)
Study: 33160341
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable formulations (e.g., vaccines, passive antibodies, chemoprophylaxis)
Study: 33389233
Drug: Spaced education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spaced education alerts through the Family Medicine Study Guide mobile app
Study: 34126630
Drug: High-dose cranberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cranberry beverage (HCb; 480 mL)
Study: 34126630
Drug: High-dose and
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose and low-dose cranberry beverages (HCb and LCb)
Study: 34126630
Drug: Low-dose cranberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose cranberry beverage (LCb; 240 mL cranberry beverage plus 240 mL placebo)
Study: 34126630
Drug: Placebo (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (480 mL)
Study: 32576084
Drug: Abemaciclib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib at full dose
Study: 32576084
Drug: Ribociclib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib at full dose
Study: 32576084
Drug: Ribociclib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib at reduced dose (400 mg)
Study: 32576084
Drug: Ribociclib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib at reduced dose (200 mg)
Study: 32576084
Drug: Palbociclib at
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib at full dose
Study: 32576084
Drug: Abemaciclib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib at reduced dose
Study: 33727798
Drug: Benfotiamine (150–1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfotiamine (150–1200 mg single ascending doses)
Study: 33727798
Drug: Benfotiamine (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfotiamine (150, 300, or 600 mg multiple ascending doses)
Study: 36300646
Drug: Inarigivir 25
Normalized name: Inarigivir
DrugBank: Inarigivir (DB15062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inarigivir 25 mg
Study: 36300646
Drug: Inarigivir 50
Normalized name: Inarigivir
DrugBank: Inarigivir (DB15062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inarigivir 50 mg
Study: 36300646
Drug: Inarigivir 100
Normalized name: Inarigivir
DrugBank: Inarigivir (DB15062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inarigivir 100 mg
Study: 36300646
Drug: Inarigivir 200
Normalized name: Inarigivir
DrugBank: Inarigivir (DB15062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inarigivir 200 mg
Study: 36300646
Drug: Inarigivir (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inarigivir (all doses)
Study: 36300646
Drug: Inarigivir (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inarigivir (all doses) during tenofovir treatment
Study: 36300646
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during tenofovir treatment
Study: 36039002
Drug: Antidepressant use
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant use in Black or African descent residents
Study: 36039002
Drug: Antidepressant use
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant use in White residents
Study: 35081076
Drug: Hydrocortisone therapy
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone therapy in immune-adaptive prevalent (IA-P) patients
Study: 35081076
Drug: Hydrocortisone therapy
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone therapy in immune-innate prevalent (IN-P) patients
Study: 33675704
Drug: Microfragmented adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microfragmented adipose tissue injection using Lipogems technology
Study: 33675704
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with hyaluronic acid injection
Study: 34447851
Drug: Neostigmine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (2.5 mg/100 ml normal saline)
Study: 34447851
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg/100 ml normal saline)
Study: 33904601
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing propolis extract, nanovitamin C and nanovitamin E, used as toothpaste three times/day for 1 month.
Study: 34561695
Drug: Cobicistat (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobicistat (150 mg q24h orally)
Study: 34561695
Drug: Cobicistat with
Normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cobicistat with GHB (25 mg/kg)
Study: 34561695
Drug: GHB alone
Normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB alone (25 mg/kg)
Study: 35604203
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine
Study: 36351185
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (control group).
Study: 33228787
Drug: On-site testing
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-site testing and antiviral treatment for influenza (baloxavir or oseltamivir depending on age and comorbidities)
Study: 33314786
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing blended with brief Cognitive Behavioural Therapy (MI‐CBT)
Study: 35086501
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of foregoing substance abuse treatments as a predictor for aftercare matching.
Study: 32302790
Drug: Focal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal therapy (FT)
Study: 32302790
Drug: Focal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal therapy (FT) with neoadjuvant agents
Study: 32302790
Drug: Focal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal therapy (FT) alone
Study: 616121608
Drug: Panretinal photocoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panretinal photocoagulation (PRP) with intravitreal Ranibizumab (RBZ) injections (study group, SG)
Study: 36372680
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (1 ml)
Study: 36372680
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (1 ml)
Study: 32615663
Drug: Saffron pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron pill
Study: 33955685
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to primary systemic therapy
Study: 33955685
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to first‐line therapy
Study: 33955685
Drug: Three or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three or more lines of systemic therapy
Study: 36243386
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 400 μg BID
Study: 36243386
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 100 μg QD